It has been about a month since the last earnings report for Adma Biologics (ADMA). Shares have added about 43.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Throughout the last three months, 4 analysts have evaluated ADMA Biologics (NASDAQ:ADMA), offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their ...

ADMA continues its demonstrated sales performance with another tremendous growth in revenue for Q1 last month. There are fundamental, sentimental and valuation facts to suggest ADMA is mispriced in my ...

California-based Palisades Investment Partners sold 398,647 shares of ADMA Biologics for an estimated $7.3 million in the third quarter. The transaction marked a full exit from ADMA, with Palisades ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company’s key product, ASCENIV, is expected to drive ...

Adma Biologics (ADMA) closed the last trading session at $14.71, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...